Prognostic value of VEGFR2 immunoexpression in glioblastoma
| Autor: | Sergi Mojal, Gemma Issus, Beatriz Bellosillo, Maria Martinez-Garcia, Joan Gibert, Pilar Navarro, Dolores Naranjo-Hans, Francesc Alameda, Montserrat Arumi-Uria |
|---|---|
| Přispěvatelé: | Fundació La Marató de TV3, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, European Commission, Generalitat de Catalunya |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty IDH1 Tissue microarray business.industry Hazard ratio medicine.disease Prognosis Primary tumor medicine.anatomical_structure VEGFR2 Internal medicine medicine cardiovascular system Immunohistochemistry Radiology Nuclear Medicine and imaging Tumor necrosis factor alpha Receptor business Glioblastoma MGMT Blood vessel |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname |
| Popis: | Glioblastoma is the most frequent and aggressive primary tumor of the central nervous system. Prognosis is poor, with a median survival of 15 months after diagnosis. Various tumor biomarkers show prognostic value for glioblastomas, including VEGFR2, which is a receptor of VEGF related to the growth of the blood vessel network. VEGFR2 expression associates with poor prognosis in some tumors. Here we studied the prognostic value of the VEGFR2 immunohistochemical expression in glioblastoma. We used tissue microarrays to analyze 45 surgically excised samples from glioblastomas. Clinical data (age, sex, and Karnofsky Performance Status [KPS]) and morphological data (tumor necrosis, palisading, and vascular thrombosis) were collected. We performed a molecular study of MGMT and IDH1 expression (which are potential prognostic factors for glioblastomas) and an immunohistochemical study of VEGFR2 expression. Our results indicate that age, KPS, tumor necrosis, vascular thrombosis, treatment (STUPP versus other), and VEGFR2 immunoreactivity were related to prognosis (p < .005). In a multivariate analysis, only age > 65 years (Hazard Ratio (HR) (95% CI): 4.9 (2.1¿11.4), p < .01), and VEGFR2 immunoexpression (HR (95% CI): 2.8 (1.3¿6.1), p = .008), were found to have a statistically significant relation to prognosis. We conclude that immunohistochemical evaluation of VEGFR2 provides added prognostic value to the study of glioblastoma. This work was supported by grants from the Fundació La Marató (num.20130332) to FA, and the Spanish Ministerio de Economía y Competitividad/ ISCIIIFEDER (PI14/00125; PI17/00199) and the "Generalitat de Catalunya" (2017/SGR/225) to PN. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|